Literature DB >> 12197603

Sheng-Mai-San is protective against post-ischemic myocardial dysfunction in rats through its opening of the mitochondrial KATP channels.

Ningyuan Wang1, Shinya Minatoguchi, Masazumi Arai, Yoshihiro Uno, Yoshio Nishida, Kazuaki Hashimoto, Chen Xue-Hai, Kazunori Fukuda, Seigo Akao, Genzou Takemura, Hisayoshi Fujiwara.   

Abstract

The present study used isolated rat hearts to investigate whether (1) Sheng-Mei-San (SMS), a traditional Chinese formulation comprising Radix Ginseng, Radix Ophiopogonis and Fructus Schisandrae, is protective against post-ischemic myocardial dysfunction, and (2) whether the cardioprotective effect of SMS is related to scavenging of hydroxyl radicals and opening the mitochondrial KATP channels. The excised hearts of male Sprague-Dawley rats were perfused on a Langendorff apparatus with Krebs-Henseleit solution with a gas mixture of 95% O2 and 5% CO2. Left ventricular end-diastolic pressure (LVEDP, mmHg), left ventricular developed pressure (LVDP, mmHg), +/-dP/dt (mmHg/s) and coronary flow (ml/min) were continuously monitored. All hearts were perfused for a total of 120 min consisting of a 30-min pre-ischemic period followed by a 30-min global ischemia and 60-min reperfusion. Lactate, lactate dehydrogenase (LDH) and 2,5-dihydroxybenzoic acid (2,5-DHBA) concentrations in the effluent were measured during reperfusion. Three days' treatment with SMS (1.67 ml/kg per day) inhibited the rise in LVEDP and improved the post-ischemic LVDP and +/-dP/dt significantly better than in the untreated control hearts during reperfusion. SMS increased the coronary flow at baseline, and during reperfusion. Pretreatment with 5-hydroxydecanoic acid (5-HD), a mitochondrial KATP channel blocker, abolished the inhibition of the rise in LVEDP, the increase in coronary flow and the improvement in LVDP and +/-dP/dt induced by SMS. SMS significantly attenuated the concentrations of lactate, LDH and 2,5-DHBA during reperfusion, but the pretreatment with 5-HD restored them; 5-HD alone did not affect the concentrations. SMS improved the post-ischemic myocardial dysfunction through opening the mitochondrial KATP channels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197603     DOI: 10.1253/circj.66.763

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Tanshinone IIA and astragaloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4.

Authors:  Juan Xie; Huan Wang; Tiebing Song; Zongren Wang; Feng Li; Jing Ma; Jun Chen; Yayun Nan; Hui Yi; Wen Wang
Journal:  Protoplasma       Date:  2012-08-08       Impact factor: 3.356

Review 2.  Therapeutic potential of ginseng in the management of cardiovascular disorders.

Authors:  Morris Karmazyn; Melissa Moey; Xiaohong Tracey Gan
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

3.  Ginseng is useful to enhance cardiac contractility in animals.

Authors:  Jia-Wei Lin; Yih-Giun Cherng; Li-Jen Chen; Ho-Shan Niu; Chen Kuei Chang; Chiang-Shan Niu
Journal:  Biomed Res Int       Date:  2014-02-04       Impact factor: 3.246

4.  Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling.

Authors:  Rajarajan A Thandavarayan; Vijayasree V Giridharan; Somasundaram Arumugam; Kenji Suzuki; Kam Ming Ko; Prasanna Krishnamurthy; Kenichi Watanabe; Tetsuya Konishi
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

5.  Extract of Sheng-Mai-San Ameliorates Myocardial Ischemia-Induced Heart Failure by Modulating Ca2+-Calcineurin-Mediated Drp1 Signaling Pathways.

Authors:  Ye Yang; Yushan Tian; Siyao Hu; Suxia Bi; Suxia Li; Yuanjia Hu; Junping Kou; Jin Qi; Boyang Yu
Journal:  Int J Mol Sci       Date:  2017-08-25       Impact factor: 5.923

6.  Psychological stress-induced oxidative stress as a model of sub-healthy condition and the effect of TCM.

Authors:  Lei Wang; Gong Muxin; Hiroshi Nishida; Chieko Shirakawa; Shinji Sato; Tetsuya Konishi
Journal:  Evid Based Complement Alternat Med       Date:  2006-11-02       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.